CCPA calls on persons to foster a child

first_img…as Foster Care Month is launchedThe Child Care and Protection Agency (CCPA) has once again dedicated the month of November to foster care; this time around, under the theme “Parenthood is more than just DNA, mentor or foster a child in need of care today”.The official launch was done on November 1, 2018, with an awareness walk from Bank of Guyana to the Georgetown seawall Band Stand.In an interview with Guyana Times on Saturday, Director of the Agency, Ann Greene called on persons to come forward and foster a child even as she highlighted the need for awareness when it comes to foster care.“Foster care is temporary care, meaning that a child for some reason or the other had to be removed from their home temporarily because something at the home isn’t right so we need to fix something. So foster care is temporary care with the ultimate goal being to return that child to their home or family. Adoption on the other hand is a legal process where the children have to get completely new parents and they become the legal parents,” she reminded. She encouraged persons to open their hearts and their homes and foster a child.She pointed out that any interested person will go through the necessary screening process before their application is processed, which includes a background and Police records check.According to Greene, the Agency will continue to focus on sensitisation in various groups, including religious organisations as well as Parent Teacher Association (PTA) groups. “The whole idea about it is to get the buy-in from the public. We want to increase our core list of foster parents because we have over 600 children in institutions,” she informed.last_img read more

Validate your antibodies to improve reproducibility Easier said than done

first_img Sign up for our daily newsletter Get more great content like this delivered right to you! Country Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe It seems like the most elementary of research principles: Make sure the cells and reagents in your experiment are what they claim to be and behave as expected. But when it comes to antibodies—the immune proteins used in all kinds of experiments to tag a molecule of interest in a sample—that validation process is not straightforward. Research antibodies from commercial vendors are often screened and optimized for narrow experimental conditions, which means they may not work as advertised for many scientists. Indeed, problems with antibodies are thought to have led many drug developers astray and generated a host of misleading or irreproducible scientific results. This week, more than 100 researchers, antibody manufacturers, journal editors, and funders met in Pacific Grove, California, to hash out standardized approaches to antibody testing. “Cell authentication is a walk in the park compared to what we need to do with antibodies,” says Leonard Freedman, president of the Global Biological Standards Institute (GBSI), a Washington, D.C.–based nonprofit that advocates for better basic research practices and that sponsored the meeting. In the coming months, the attendees hope to come up with a scoring system that will identify the most reliable antibodies for a given type of experiment and ultimately (they hope) make results more reproducible across experiments.Antibodies are typically made in animals such as rabbits or goats, by injecting a protein of interest and waiting for the animal’s B cells to respond to the foreign molecule with the Y-shaped proteins, which can be isolated from its blood. But batches of the same antibody from different animals may cross-react with different proteins. And it’s hard to trace a given batch to its origin, because antibodies are often relabeled and resold by another vendor under a new name, Freedman says. Emailcenter_img Click to view the privacy policy. Required fields are indicated by an asterisk (*) Validating the roughly 2.5 million commercially available antibodies that react to human proteins is a mammoth task, acknowledged Mathias Uhlén, a microbiologist at the Royal Institute of Technology in Stockholm and a member of the meeting’s steering committee, in a press briefing. He expects that antibody providers would do the testing and publicize their scores to make their products more competitive. Journals and funding agencies would in turn need to favor research that uses well validated antibodies, he said.This week’s meeting is one of several efforts to attack what some consider a reproducibility crisis on the antibody front. In an online survey of 504 researchers published by GBSI this summer, more than half of respondents said they had received no training on how to validate antibodies. Experts in an ad hoc international antibody validation working group published a commentary earlier this month in Nature Methods advocating for application-specific antibody testing. Working groups from the meeting intend to publish white papers on their scoring system in journals over the next 6 months. With reporting by Meredith Wadman.last_img read more